We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Niox Group plc (NIOX) ORD GBP0.0008

Sell:68.00p Buy:68.60p 0 Change: 3.20p (4.57%)
FTSE AIM 100:0.54%
Market closed Prices as at close on 12 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 3.20p (4.57%)
Market closed Prices as at close on 12 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Change: 3.20p (4.57%)
Market closed Prices as at close on 12 July 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.

Contact details

Hayakawa Building
The Oxford Science Park
United Kingdom
+44 (01865) 405560

Important dates

Future events
There are no future events available.
Past events
Final dividend payment date 24 June 2024 24/06/24
Final ex-dividend date 23 May 2024 23/05/24
AGM 22 May 2024 22/05/24
Annual report 22 April 2024 22/04/24
Final results 26 March 2024 26/03/24
Trading Announcement 18 January 2024 18/01/24
Interim results 26 September 2023 26/09/23
Special dividend payment date 15 September 2023 15/09/23
Special ex-dividend date 17 August 2023 17/08/23
Trading Announcement 18 July 2023 18/07/23

General stock information

Market cap:
£283.26 million
Shares in issue:
424.05 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence

Key personnel

  • Ian Johnson
    Executive Chairman of the Board
  • Michael Roller
    Chief Financial Officer, Executive Director
  • Jonathan Emms
    Chief Operating Officer, Executive Director
  • Sarah Duncan
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.